NCT04246047 · OUTCOME

Time to Progression (TTP)

Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma · Source last updated 2026-04-23

This outcome was registered, but no numerical results were posted in the captured record.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: Up to 73 months

What was measured

TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first.

Groups in this outcome

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

anticipated Posting Date: 2027-06
denom Units Selected: Participants
description: TTP is defined as time from the date of randomization until the earliest date of documented date of disease progression or death, whichever occurs first.
reporting Status: NOT_POSTED
time Frame: Up to 73 months
title: Time to Progression (TTP)
type: SECONDARY

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice